Please assess the completion status of the following clinical trial:

Trial Title: Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Acute coronary syndrome (unstable angina, NSTEMI, and STEMI)~* Significant coronary artery stenosis (\>50% by visual estimate) eligible for coronary stenting~* Between 20 and 75 years of age~* Body weight ≥ 60kg~* Aspirin dose of 100 mg is recommended~* Ability to understand and to comply with the study protocol~Exclusion Criteria:~* Prior history of ischemic or hemorrhagic stroke or transient ischemic attack, or sub-arachnoids hemorrhage~* fibrinolytic or abciximab therapy within 48 hours of entry or randomization into the study~* vitamin K antagonist~* History of intolerance or allergy to ASA or approved thienopyridines (ticlopidine, clopidogrel, or prasugrel)~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)~* active pathological bleeding or history of bleeding diathesis~* Thrombocytopenia (platelets \< 100,000/mm3)~* Severe hepatic impairment (Child Pugh class C).~* a condition associated with poor treatment compliance, including dementia or mental illness

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: ACTIVE_COMPARATOR): Fixed-dose Prasugrel of 10 mg/d
- group 2 (Type: ACTIVE_COMPARATOR): Fixed-dose Prasugrel of 5 mg/d
- group 3 (Type: ACTIVE_COMPARATOR): Phenotype-based prasugrel dose~* If patients show PRU \< 85, prasugrel dose will be reduced by 5 mg/d.~* If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d.

Based on this trial design, predict the completion outcome and termination type (if applicable).